Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
By Charm Therapeutics gains investment from NVentures for cancer therapeutics
Charm Therapeutics has announced investment from NVentures – NVIDIA’s venture investment arm. This represents a major milestone for Charm and means it will be able to deliver more on its research and development (R&D) activities for novel oncology...
Redx has been presented with a commemorative plaque at its HQ at Alderley Park, in recognition of its discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's cancer treatment Jaypirca.
Two contract research organizations working in the clinical trial and research fields have benefited from investment from Iberian private equity firm, Henko Partners.
Neuraxapharm Group, a European-based pharmaceutical company that focuses on central nervous system (CNS) announced last week that it had signed a binding agreement to divest API developer and manufacturer company, Inke, to private equity manager Keensight...
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
The company announces plans to reorganize its business to focus on design-and-deployment engagements for on-site implementation of automated cloud labs.
The Institute for Population and Precision Health (IPPH) at the University of Chicago has joined private biotech company, Freenome, to become its partner as part of a study.
Unifying medicinal development processes and data within a connected technology ecosystem will enhance collaboration, two partnering companies using a development cloud have said.
Dutch biopharmaceutical company, Pharming Group PV, has sent its first commercial shipments of a drug to treat a rare, primary immunodeficiency, to the US.
OSP spoke to Vladamir Penkrat, head of safety and regulatory and Shuba Rao a senior director at Indegene, a life sciences digital company about a paper they recently published called 'Challenges and Future of PV Compliance' about the direction...
TWO US clinical investigator sites have been opened for a phase 1 clinical trial for patients with soft tissue sarcoma and the first patient has been dosed.
The naloxone hydrochloride nasal spray will be made available over-the-counter, therefore not requiring a prescription, in an effort to reduce deaths from opioid abuse.
An agreement has been reached to promote Cingulate Inc’s ‘first true entire active day medication’ designed to treat attention deficit hyperactivity disorder (ADHD).
The company launches its new ZS300 sensor, ZB200 bridge and Android sensor discovery app, which will be made available for use with the supply chains of the pharma and food industries.
Earlier this year, Akorn Pharmaceuticals fell into bankruptcy, and now an alliance of stakeholders have released a report outlining potential supply disruption to a number of medications.
The funding will be split between 17 US non-profit organizations this year, as the company reveals the broader progress it has made towards its long-term inclusion and diversity goals.
Oversubscribed, series B financing for Noema Pharma’s clinical stage assets has been successfully closed raising $112 million from new and existing investors.
Poolbeg Pharma plc has been granted a patent by the US Patent and Trademark Office (USPTO) for ways of treating hypercytokinaemia using a small molecule immunomodulator.
Kemiex has secured equity investments from the strategic investment arm of CME Group, CME Ventures, the global data and analytics company DTN, as well as the family office Wille Finance.
The Dutch company Pharming Group N.V. has switched its rare disease drug leniolisib from an accelerated assessment to a regular review with the European Medicines Agency (EMA).
The report compiles several of the key factors that are driving the growth of antimicrobial resistance, highlighting the pharmaceutical industry as a key economic sector driving the issue.
Here at OutsourcingPharma, we put our audience at the heart of what we do. For many years, we have provided our readers with a 360-degree view of the pharma landscape and our editorial standards remain unsurpassed.
